Shopping Cart
Remove All
Your shopping cart is currently empty
NLRP3-IN-41 administered at doses of 40 and 80 mg/kg through intragastric (i.g.) delivery over a span of 10 days, successfully alleviated the symptoms of colitis induced by DSS in both C57BL/6 and ICR mice.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $1,520 | 4-6 weeks | 4-6 weeks | |
| 50 mg | $1,980 | 4-6 weeks | 4-6 weeks | |
| 100 mg | $2,500 | 4-6 weeks | 4-6 weeks |
| Description | NLRP3-IN-41 administered at doses of 40 and 80 mg/kg through intragastric (i.g.) delivery over a span of 10 days, successfully alleviated the symptoms of colitis induced by DSS in both C57BL/6 and ICR mice. |
| In vitro | NLRP3-IN-41 (5-15 μM, 24 h) effectively inhibits the induction of IL-1β by LPS (100 ng/mL) and ATP (5 mM) in THP-M and also suppresses AIM2 and NLRC4 inflammasomes. |
| In vivo | NLRP3-IN-41 administered at doses of 40 and 80 mg/kg through intragastric (i.g.) delivery over a span of 10 days, successfully alleviated the symptoms of colitis induced by DSS in both C57BL/6 and ICR mice. |
| Molecular Weight | 442.55 |
| Formula | C22H22N2O4S2 |
| Cas No. | 1209698-02-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.